Traci McCarty | executive |
Alexander Hardy | executive |
Henry Fuchs | executive |
Brian Mueller | executive |
Salveen Richter | analyst |
Akash Tewari | analyst |
Jessica Fye | analyst |
Philip Nadeau | analyst |
Geoffrey Meacham | analyst |
Jeffrey Ajer | executive |
Eliana Merle | analyst |
Joseph Schwartz | analyst |
Nishant Gandhi | analyst |
Mohit Bansal | analyst |
Huidong Wang | analyst |
Julian Pino | analyst |
Vikram Purohit | analyst |
Tim Lugo | analyst |
Olivia Brayer | analyst |
Konstantinos Biliouris | analyst |
Jack Allen | analyst |
David Lebowitz | analyst |
Luca Issi | analyst |
Thank you for standing by, and welcome to the BioMarin Pharmaceutical Fourth Quarter and Full Year 2023 Conference Call. I would now like to welcome Traci McCarty, Head of Investor Relations to begin the call. Traci, over to you.
Thank you, Mandy. Thank you, everyone, for joining us today.